Maravai Lifesciences Holdings, Inc.
(NASDAQ : MRVI)

( )
MRVI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.57%283.291.5%$876.09m
GILDGilead Sciences, Inc. -0.02%87.961.0%$686.29m
MRNAModerna, Inc. -1.36%173.540.0%$642.89m
REGNRegeneron Pharmaceuticals, Inc. -1.06%747.472.6%$489.87m
VRTXVertex Pharmaceuticals, Inc. -1.82%311.811.9%$475.10m
BIIBBiogen, Inc. -0.44%291.471.8%$409.07m
ILMNIllumina, Inc. -3.69%205.983.2%$225.66m
BMRNBioMarin Pharmaceutical, Inc. -1.27%102.224.2%$161.73m
BNTXBioNTech SE -3.05%161.620.0%$160.60m
AXSMAxsome Therapeutics, Inc. -2.63%75.261.6%$141.48m
SNSSSunesis Pharmaceuticals, Inc. -6.51%2.010.7%$140.51m
MRTXMirati Therapeutics, Inc. -22.89%71.521.6%$125.68m
HALOHalozyme Therapeutics, Inc. 0.79%56.3818.4%$81.14m
NVAXNovavax, Inc. -4.71%16.7875.3%$80.38m
IMGOImago BioSciences, Inc. 0.00%35.860.0%$59.53m

Company Profile

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.